The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Novel vaccine technologies for the 21st century
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Messenger RNA (mRNA)-based therapy recently emerged as an effective platform for treatment of infectious diseases and cancer (Jackson et al., 2020; Mascola and Fauci, 2020).”
From A thermostable mRNA vaccine against COVID-19 (2020) · cites this paper as Mascola and Fauci, 2020
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination
Nemes, E., Geldenhuys, H. D., Rozot, V., Rutkowski, K. T., Ratangee, F., Bilek, N., Mabwe, S., Makhethe, L., Erasmus, M., Toefy, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714021 · Cited by 653
Final Analysis of a Trial of M72/AS01 E Vaccine to Prevent Tuberculosis
Tait, D. R., Hatherill, M., Van Der Meeren, O., Ginsberg, A. M., Van Brakel, E., Salaun, B., Scriba, T. J., Akite, E. J., Ayles, H. M., Bollaerts, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1909953 · Cited by 605
Prevention of tuberculosis in macaques after intravenous BCG immunization
Darrah, P. A., Zeppa, J. J., Maiello, P. A., Hackney, J. A., Wadsworth, M. H., Hughes, T. K., Pokkali, S., Swanson, P. A., Grant, N. L., Rodgers, M., et al. (2020) · Nature · doi:10.1038/s41586-019-1817-8 · Cited by 592
Feldman, R. A., Fuhr, R., Smolenov, I., (Mick) Ribeiro, A., Panther, L., Watson, M., Senn, J. J., Smith, M., Almarsson, Ӧ., Pujar, H. S., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.04.074 · Cited by 454
Marcandalli, J., Fiala, B., Ols, S., Perotti, M., de van der Schueren, W., Snijder, J., Hodge, E. A., Benhaim, M. A., Ravichandran, R., Carter, L. P., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.046 · Cited by 444
A proof of concept for structure-based vaccine design targeting RSV in humans
Crank, M. C., Ruckwardt, T. J., Chen, M., Morabito, K. M., Phung, E., Costner, P. J., Holman, L. A., Hickman, S. P., Berkowitz, N. M., Gordon, I. J., et al. (2019) · Science · doi:10.1126/science.aav9033 · Cited by 333
Self-citationPardi, N., Parkhouse, K., Kirkpatrick, E., McMahon, M., Zost, S. J., Mui, B. L., Tam, Y. K., Karikó, K., Barbosa, C. J., Madden, T. D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05482-0 · Cited by 281
Nabel, G. J. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1204186 · Cited by 271
Chasing Seasonal Influenza — The Need for a Universal Influenza Vaccine
Paules, C. I., Sullivan, S. G., Subbarao, K., & Fauci, A. S. (2017) · New England Journal of Medicine · doi:10.1056/nejmp1714916 · Cited by 256
Self-citationNew Promise for Vaccines against Tuberculosis
Bloom, B. R. (2018) · New England Journal of Medicine · doi:10.1056/nejme1812483 · Cited by 27
Research works printed but not linked: 1
- Darrah, P. A. et al. Prevention of tuberculosis in nonhuman primates following intravenous BCG immunization. Nature (in the press).
Cited by
Sorted by citations
A guide to vaccinology: from basic principles to new developments
Pollard, A. J., & Bijker, E. M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00479-7 · Cited by 1,593
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 852
A thermostable mRNA vaccine against COVID-19
Zhang, N.-N., Li, X.-F., Deng, Y.-Q., Zhao, H., Huang, Y.-J., Yang, G., Huang, W.-J., Gao, P., Zhou, C., Zhang, R.-R., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.024 · Cited by 671
“Messenger RNA (mRNA)-based therapy recently emerged as an effective platform for treatment of infectious diseases and cancer (Jackson et al., 2020; Mascola and Fauci, 2020).”
Lipids and Lipid Derivatives for RNA Delivery
Zhang, Y., Sun, C., Wang, C., Jankovic, K. E., & Dong, Y. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00244 · Cited by 649
An in silico deep learning approach to multi-epitope vaccine design: a SARS-CoV-2 case study
Yang, Z., Bogdan, P., & Nazarian, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-81749-9 · Cited by 271
Metadata
- Authors
- Mascola, J. R., & Fauci, A. S.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Fauci, Anthony S.
- Venue
- Nature Reviews Immunology
- Published
- 2019-11-11
- Volume
- 20
- Issue
- 2
- Pages
- 87-88
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- PMC
- PMC7222935
- OpenAlex
- W2983736730
- Cited by
- 171
- References
- 10
- Citations by year
- 2026: 13 · 2025: 24 · 2024: 33 · 2023: 24 · 2022: 35 · 2021: 24 · 2020: 17 · 2019: 1
- FWCI
- 7.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- vaccine development, gene-based vaccines, tuberculosis vaccine, influenza vaccination, RSV vaccine, adjuvant development
- MeSH terms
- Drug Development, Adjuvants, Immunologic, BCG Vaccine, Humans, Influenza, Human, Influenza Vaccines, Recombinant Proteins, RNA, Messenger, Vaccines, Vaccines, Synthetic, Viral Fusion Proteins, Respiratory Syncytial Virus, Human, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Vaccines, Tuberculosis Vaccines, Latent Tuberculosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
